Diabetic Macular Edema

Discussing how end of study results from the phase 2 LADDER trial inform clinicians on the use of PDS with ranibizumab.

New research suggests the prevalence of depression and anxiety is greater among patients with diabetic retinopathy.

A new analysis of STAIRWAY from ARVO 2020 is shedding additional light on the effects of faricimab use.

New research from an NIH-funded study suggest 0.004 mg bevacizumab could be an effective treatment for type 1 retinopathy of prematurity.

An analysis from the Women's Health Initiative has uncovered a potential link between visual impairment and risk of incident dementia.

Results of the 5-year Protocol T extension study are offering insight into the differences in real-world treatment and study protocol with anti-VEGF treatments.

Study data suggested that up to 80% of patients with Parkinson disease may have ophthalmologic symptoms.

Vitreoretinal surgeon discusses what ophthalmologists would need to see from a new treatment to replace aflibercept as first-line treatment for wet AMD.

Results of a phase 2 trial from Oculis S.A. support use of their novel eye drop formulation for the treatment of diabetic macular edema.

Discussing how the approval of brolucizumab in late 2019 impacts current treatment algorithms for wet age-related macular degeneration.

New Penn Medicine data break down the impact each missed visit can have on treatment outcomes for patients with AMD.

Discussing which potential AMD treatments retina specialists are most excited about moving forward.

Discussing the most effective ways new therapies can reduce the treatment burden of current age-related macular degeneration treatments.

A submitted column on how to properly care for patients suffering from vision loss from the founder and medical director of Focus Clinics in London.

The IGF-1R inhibitor becomes the first therapy indicated for the rare eye condition.

Results of the Canadian CANTREAT study are debunking the notion anti-VEGF injections with ranibizumab need to take place monthly as opposed to a treat-and-extend regimen.

A decade of fine-tuning proven therapies and embracing advancing clinical technology has put ophthalmology in a rare space.

A study from SUNY University at Buffalo has found adherence to a Western diet could contribute to the development of late age-related macular degeneration.

Maria Woodward, MD, MSc, discusses the impact of reducing opioid prescriptions following corneal surgery.

Katherine Talcott, MD, of the Cole Eye Institute, discusses the results of a study she co-authored from AAO 2019 that examined visual acuity outcomes after cataract extraction with IOL implantation with diabetic eyes.

Rishi Singh, MD, of the Cole Eye Institute, discusses the results of an analysis of VIEW trial participants he presented at AAO 2019.

Sumayya Ahmad, MD, assistant professor of ophthalmology at Icahn School of Medicine at Mount Sinai, discusses the results of a study she co-authored examining demographic associations with varying forms of astigmatism

Michael Stewart, MD, of Mayo Clinic Jacksonville, discusses the results of 2 phase 2a studies examining the use of AKST4290 in treatment naive and refractory neovascular age-related macular degeneration.

Aleksandra Rachitskaya, MD, of Cole Eye Institute, discusses a presentation she led at AAO 2019 on novel imaging and surgical techniques.

A phase 1b study, which was presented by Charles Wykoff, MD, PhD, at AAO 2019, found the novel anti-VEGF therapy KSI-301 shows promise for treating a slew of retinal diseases.